COVID-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said on Monday.The Ad5-nCoV is one of China’s eight vaccine candidates approved for human trials at home and abroad for the respiratory disease caused by the new coronavirus.
The shot also won approval for human testing in Canada.China’s Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing.
The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS). Coronavirus drug remdesivir to cost $2,340 per patient in the U.S.